Fredun Pharmaceuticals Ltd

Valuation multiple: P/E of 43.12 is elevated; assess whether near-term earnings growth justifies this multiple relative to peers in the pharma sector

Operational volatility: quarterly revenue fluctuates sharply (₹13–45 Cr range) and one quarter resulted in a loss (Mar 2020, ₹–0.21 Cr net profit); understand whether this reflects seasonality, customer concentration, or execution inconsistency

Margin sustainability: OPM volatility across quarters (3.2% to 6.96% historical range vs. current 11.56%) requires clarification on whether recent margin improvement is structural or driven by temporary factors

Moderate leverage: D/E ratio of 1.18 constrains financial flexibility; review debt maturity schedules and refinance risk in a rising interest-rate environment

Revenue growth trajectory: quarterly revenue expanded from ₹31.43 Cr (Sep 2019) to ₹45.1 Cr (Dec 2020); verify if this momentum has continued post-Mar 2021

Operating margin recovery: current OPM of 11.56% substantially exceeds the historical quarterly range of 3.2–6.96%; clarify whether this reflects volume growth, pricing power, or cost discipline

Profitability stabilisation: after a Mar 2020 loss of ₹0.21 Cr, the company returned to consistent profitability (₹0.73–1.34 Cr quarterly); assess if this signals durable operational recovery

Pharmaceutical sector expansion: Indian pharma sector growth from rising healthcare demand and export opportunities; verify the company's therapeutic focus, product pipeline, and competitive positioning to evaluate market-share capture potential